Barclays Capital Gives Overweight Rating to Aetna (AET)
Several other analysts have also recently commented on the stock. Analysts at Goldman Sachs (NYSE: GS) downgraded shares of Aetna from a “neutral” rating to a “sell” rating in a research note to investors on Wednesday, May 9th. They now have a $45.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Aetna from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, May 2nd. They now have a $47.00 price target on the stock. Finally, analysts at Oppenheimer (NYSE: OPY) cut their price target on shares of Aetna from $48.00 to $47.00 in a research note to investors on Friday, April 27th.
Aetna opened at 40.83 on Tuesday. Aetna has a 1-year low of $33.43 and a 1-year high of $51.14. The company has a market cap of $14.184 billion and a price-to-earnings ratio of 7.95.
Aetna last released its earnings data on Thursday, April 26th. The company reported $1.34 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.39 by $0.05. Aetna’s revenue was up 6.2% compared to the same quarter last year. Analysts expect that Aetna will post $1.34 EPS next quarter.
Aetna Inc. (Aetna) is a diversified health care benefits company, serving approximately 35.3 million people.